Aarti Drugs Q3 FY26: Rs 91 cr PAT, Rs 2 interim dividend
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.3 pts less than Nifty Microcap 250 and 6.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs posted Q3 FY26 standalone revenue of Rs 601.71 cr versus Rs 555.6 cr YoY, with profit after tax of Rs 91.27 cr. Nine-month PAT was Rs 140.54 cr. Board declared Rs 2 per share interim dividend (20%) with Feb 9, 2026 as record date. New Sayakha Gujarat plant began commercial operations in September 2025. Three senior managers were added to the Senior Management Personnel list.
Strong Q3 earnings growth and dividend declaration are positive for shareholders. New plant supports revenue growth; watch margin trends.